Matthew A. Cooper
Oprichter bij Inflazome Ltd.
Oorsprong van het eerstegraads netwerk van Matthew A. Cooper
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
35
| Private Company | Investment Managers | 35 |
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK
7
| Extinct | Electronic Equipment/Instruments | 7 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Matthew A. Cooper via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Stanford University | College/University | Masters Business Admin Undergraduate Degree | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Founder | |
| University of Cambridge | College/University | Doctorate Degree Masters Business Admin | |
Cambridge Drug Discovery Holdings Ltd.
 Cambridge Drug Discovery Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Charles River Laboratories International, Inc., Cambridge Drug Discovery Holdings Ltd. is a company that researches potential new drugs for the treatment of cancer. The company is based in Cambridge, UK. Cambridge Drug Discovery Holdings was acquired by Charles River Discovery Research Services UK Ltd., part of Charles River Laboratories International, Inc. from November 14, 2005 on June 11, 2001 for $38 million. The British company was founded by Barry Kenny, Jonathan Mark Treherne. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Director/Board Member | |
| University of London | College/University | Undergraduate Degree Doctorate Degree | |
| University of Bristol | College/University | Undergraduate Degree Undergraduate Degree | |
| Trinity College Dublin | College/University | Masters Business Admin Corporate Officer/Principal | |
Chroma Therapeutics Ltd.
 Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| University of Amsterdam | College/University | Doctorate Degree Undergraduate Degree Corporate Officer/Principal | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
| University of Groningen | College/University | Graduate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| Vrije Universiteit Amsterdam | College/University | Undergraduate Degree Graduate Degree | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| MERUS N.V. | Biotechnology | Chief Executive Officer Director/Board Member | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Founder Director/Board Member | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Chairman Director/Board Member | |
Staten Biotechnology BV
 Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Metrion Biosciences Ltd.
 Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Biotechnology | Director/Board Member Director/Board Member | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer Chairman Founder | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Director/Board Member Founder | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
Oxitope Pharma BV
 Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| ENGENE HOLDINGS INC. | Biotechnology | Director/Board Member Director/Board Member | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Director/Board Member |
Statistieken
Internationaal
| Nederland | 16 |
| Verenigd Koninkrijk | 13 |
| Verenigde Staten | 8 |
| Zwitserland | 6 |
| Canada | 4 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 10 |
| Commercial Services | 7 |
| Health Services | 4 |
| Finance | 4 |
Operationeel
| Director/Board Member | 311 |
| Corporate Officer/Principal | 90 |
| Chairman | 57 |
| Founder | 45 |
| Independent Dir/Board Member | 41 |
Sterkste connecties
| Insiders | |
|---|---|
| Timothy Haines | 36 |
| Hugo Slootweg | 34 |
| Patrick Volkert Vink | 30 |
| Nanna Liebach Lüneborg | 29 |
| Florent Gros | 28 |
| Michael Hayden | 27 |
| Peter Andersen | 26 |
| Petri T. Vainio | 24 |
| Stephen William Bunting | 22 |
| David Hirsch | 20 |
| Geert-Jan Mulder | 17 |
| Sander J. van Deventer | 17 |
| Manus Rogan | 15 |
| Marco Boorsma | 15 |
| Jasper Bos | 15 |
- Beurs
- Insiders
- Matthew A. Cooper
- Bedrijfsconnecties
